Low risk — use of or exposure to this product is not likely to cause adverse health consequences.
Abilify (aripiprazole) Recalled by Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. Due to Cross Contamination with Other Products
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. directly.
Affected Products
Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13
Quantity: 108,192/30 count bottles or 7 count blister packs
Why Was This Recalled?
Cross Contamination with Other Products
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. has 4 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report